TY  - CHAP
M1  - Book, Section
TI  - Chapter 33. Clostridium Difficile Infections
A1  - Traugott, Kristi
A2  - Attridge, Rebecca L.
A2  - Miller, Monica L.
A2  - Moote, Rebecca
A2  - Ryan, Laurajo
PY  - 2013
T2  - Internal Medicine: A Guide to Clinical Therapeutics
AB  - Alteration  of  endogenous  colonic  flora  →  ingestion  of  Clostridium  difficile  spores  →  colonization  →  toxin  release  →  necrosis  &  inflammationDefinitions  of  C.  difficile  (C.  diff)  infection:  presence  of  diarrhea  (3  or  more  unformed  stools  in  ≤24h)  &  presence  of  toxigenic  C.  diff  or  its  toxins  or  pseudomembranous  colitis  by  colonoscopic  or  histopathological  findings  (Infect  Control  Hosp  Epidemiol  2010;31:431)  Risk  factors:  advanced  age,  duration  of  hospitalization,  antimicrobial  use  (esp.  clindamycin,  cephalosporins,  fluoroquinolones),  chemotherapy,  immunosuppression,  GI  surgery  or  manipulation,  acid-suppressing  medications  (H2  blockers  &  PPIs),  feeding  tubes  (especially  postpyloric)  (Infect  Control  Hosp  Epidemiol  2010;31:431;  Clin  Infect  Dis  2008;46:S19)  
SN  - 
PB  - The McGraw-Hill Companies
CY  - New York, NY
Y2  - 2024/04/20
UR  - accesspharmacy.mhmedical.com/content.aspx?aid=57292510
ER  -